Literature DB >> 10898179

Judging the therapeutic value of lymph node dissections for melanoma.

A D Chan1, R Essner, L A Wanek, D L Morton.   

Abstract

BACKGROUND: The management of the regional lymph nodes remains controversial for early-stage melanoma and for those patients with lymph node metastases; American Joint Committee on Cancer stage III. This study examines the importance of quality of the surgical resection measured by the extent of lymph node dissection (quartile of the total number of lymph nodes removed) to determine if this factor is an important prognostic factor for survival. STUDY
DESIGN: We reviewed our computer-assisted database of more than 8,700 melanoma patients prospectively collected from 1971 through the present to identify patients who underwent lymph node dissection for stage III melanoma. We included only patients who had their nodal dissections performed at our institute. Patients who underwent sentinel lymph node dissection were excluded. These patients were then analyzed as a group and by individual lymphatic basins: cervical, axillary, and inguinal basins. Univariate and multivariate analyses were used to examine the model that included tumor burden, thickness of the primary melanoma, gender, age, clinical status of the lymph nodes (palpable versus not palpable), and the primary site. The survival and recurrence rates were analyzed using the Cox proportional hazards model.
RESULTS: Five hundred forty-eight patients underwent regional lymph node dissections. Of these patients, 214 underwent axillary dissections, 181 inguinal dissections, and 153 cervical dissections. The extent of the nodal dissections was based on the quartile of nodes excised, ranging from 1 to 98 (mean +/- SD = 25.8 +/- 15.8). Patients were stratified by tumor burden and quartile of number of lymph nodes removed. The overall 5-year survival of patients with four or more lymph nodes having tumor and the highest quartile of lymph nodes removed was 44% and was 23% for the lowest quartile of total lymph nodes excised (p = 0.05). By univariate analysis, tumor burden (p = 0.0001), quartile of total lymph nodes removed (p = 0.043), and primary site (p = 0.047) were statistically significant for predicting overall survival. Gender, clinical status of the nodes, primary tumor thickness, age, and dissected basin were not significant (p > 0.05). By multivariate analysis only the tumor burden (p = 0.0001) and quartile of lymph nodes resected (p = 0.044) were statistically significant.
CONCLUSIONS: The extent of lymph node dissection for melanoma when analyzed by quartiles is an independent factor in overall survival. This factor appears to be more important with increasing tumor burden in the lymphatic basin. The extent of lymph node dissection should be considered as a prognostic factor in the design of clinical trials that involve stage III melanoma.

Entities:  

Mesh:

Year:  2000        PMID: 10898179     DOI: 10.1016/s1072-7515(00)00313-6

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  4 in total

1.  Combined endoscopic and open inguinal dissection for malignant melanoma.

Authors:  Claus Schneider; Jens P Brodersen; Hubert Scheuerlein; Carsten Tamme; Hans Lippert; Ferdinand Köckerling
Journal:  Langenbecks Arch Surg       Date:  2003-03-11       Impact factor: 3.445

Review 2.  The role of para-aortic lymphadenectomy in endometrial cancer.

Authors:  Mariam M AlHilli; Andrea Mariani
Journal:  Int J Clin Oncol       Date:  2013-02-15       Impact factor: 3.402

3.  A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.

Authors:  Georgia M Beasley; Colin Parsons; Gloria Broadwater; M Angelica Selim; Suroosh Marzban; Amy P Abernethy; April K S Salama; Edward A Eikman; Terence Wong; Jonathan S Zager; Douglas S Tyler
Journal:  Ann Surg       Date:  2012-08       Impact factor: 12.969

4.  Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.

Authors:  Donald L Morton; Eddy C Hsueh; Richard Essner; Leland J Foshag; Steven J O'Day; Anton Bilchik; Rishab K Gupta; Dave S B Hoon; Mepur Ravindranath; J Anne Nizze; Guy Gammon; Leslie A Wanek; He-Jing Wang; Robert M Elashoff
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.